Article Dans Une Revue (Article De Synthèse) Clinics and Research in Hepatology and Gastroenterology Année : 2025

An Expert Consensus Delphi Panel in MetALD: Opportunities and Challenges in Clinical Practice.

V. Ajmera
  • Fonction : Auteur
J. P. Arab
  • Fonction : Auteur
D. Q. Huang
  • Fonction : Auteur
C. Hsu
  • Fonction : Auteur
B. P. Lee
  • Fonction : Auteur
M. Thiele
  • Fonction : Auteur
F. Tavaglione
  • Fonction : Auteur
M. Tincopa
  • Fonction : Auteur
E. Pose
  • Fonction : Auteur
L. A. Adams
  • Fonction : Auteur
W. Alazawi
  • Fonction : Auteur
M. Arrese
  • Fonction : Auteur
R. Bataller
  • Fonction : Auteur
A. Duseja
  • Fonction : Auteur
S. Liangpunsakul
  • Fonction : Auteur
M. R. Lucey
  • Fonction : Auteur
J. Mellinger
  • Fonction : Auteur
A. Nakajima
  • Fonction : Auteur
V. Ratziu
  • Fonction : Auteur
N. Reau
  • Fonction : Auteur
M. E. Rinella
  • Fonction : Auteur
M. Thursz
  • Fonction : Auteur
V. W. Wong
  • Fonction : Auteur
P. S. Kamath
  • Fonction : Auteur

Résumé

Background & Aims Metabolic dysfunction- and alcohol-associated liver disease (MetALD) is a recently defined entity for individuals with liver steatosis, metabolic dysfunction, and increased alcohol intake. However, the current definition of MetALD poses multiple challenges in clinical practice and research. In this Delphi consensus, we provide practical recommendations for the clinical assessment and management of MetALD to address current clinical challenges in MetALD. Methods We used a modified Delphi process, including 2 surveys involving a panel of 28 experts from 10 countries spanning 4 continents. We predefined consensus as requiring an ≥80% agreement. Results The panel reached consensus on 28 statements. Recommendations emphasize the importance of a comprehensive assessment of patients with presumed MetALD, including the quantification of alcohol intake using validated questionnaires and the use of objective biomarkers of alcohol use, such as phosphatidylethanol. The need to reassess metabolic risk factors and liver disease after a period of alcohol abstinence was highlighted to distinguish the primary driver of liver injury. Noninvasive tests were recommended to assess liver disease severity, whereas routine liver biopsy was deemed unnecessary unless other diagnoses were suspected. Comprehensive management strategies should involve multidisciplinary care focusing on lifestyle modifications, alcohol reduction or cessation, weight loss, and exercise. Finally, the panel identified significant gaps in knowledge, advocating for standardized research protocols, longitudinal studies, exploration of pathophysiological mechanisms to inform precision medicine approaches, and the validation of quantitative alcohol biomarkers for identifying MetALD. Conclusions This Delphi consensus provides clear recommendations for the clinical assessment and management of MetALD, addressing the unique challenges posed by this condition.

Fichier non déposé

Dates et versions

hal-05325385 , version 1 (22-10-2025)

Identifiants

Citer

Luis Antonio Diaz, V. Ajmera, J. P. Arab, D. Q. Huang, C. Hsu, et al.. An Expert Consensus Delphi Panel in MetALD: Opportunities and Challenges in Clinical Practice.. Clinics and Research in Hepatology and Gastroenterology, 2025, Clinics and Research in Hepatology and Gastroenterology, ⟨10.1016/j.cgh.2025.02.017⟩. ⟨hal-05325385⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

  • More